Novo Nordisk's Ziltivekimab Fails Pivotal Heart Trial

Ziltivekimab reduced cardiovascular inflammation exactly as designed, yet failed to cut heart attacks, strokes, or cardiovascular death, sending Novo Nordisk shares down sharply.

Key Takeaways

• Ziltivekimab achieved full biological target engagement, cutting IL-6 and hsCRP as intended, but did not reduce major cardiovascular events versus placebo in the 6,376-patient ZEUS trial.
• Novo Nordisk shares fell nearly 10 percent on the news. The result triggers a non-cash impairment charge in the third quarter but leaves full-year 2026 profit guidance unchanged.
• The miss recalls CANTOS, the 2017 trial that proved inflammation as a cardiovascular target. Novo’s HERMES and ARTEMIS studies continue toward 2027 readouts.

A Trial That Delivered Everything Except the Answer

Novo Nordisk built its case for ziltivekimab on a hypothesis that had waited more than a decade for a definitive test: that inflammation, not cholesterol alone, drives a meaningful share of cardiovascular risk, and that silencing the right molecular signal could translate into fewer heart attacks and strokes. On Friday, the company reported that the drug had done its job at the cellular level and nothing more. The ZEUS trial showed that ziltivekimab produced the expected reductions in free interleukin-6 and high-sensitivity C-reactive protein, yet this did not translate into a reduction in major adverse cardiovascular events compared with placebo, with a hazard ratio of 0.99 and a 95 percent confidence interval spanning 0.88 to 1.11.

The scale of the study leaves little room to blame statistical noise. ZEUS enrolled 6,376 participants with established atherosclerotic cardiovascular disease, chronic kidney disease, and elevated inflammatory markers, randomized evenly to once-monthly subcutaneous ziltivekimab or a matching placebo on top of standard care. The baseline population was, by design, among the sickest cohorts studied in cardiovascular medicine in recent years: a mean age of 69.5 years, nearly two thirds living with diabetes, more than four in ten already diagnosed with heart failure, and kidney function reduced to a mean filtration rate of 44.5 mL per minute. If IL-6 inhibition could not move the needle in a population this laden with risk, it raises a genuine question about where, if anywhere, the approach still has room to work.

What makes the result unusual is the cleanliness of the failure. There was no imbalance in dropout rates, no confounding safety signal beyond a modest increase in serious infections, and no ambiguity in the primary analysis. Overall adverse event rates matched placebo closely, and all-cause mortality showed no difference between arms. Novo Nordisk’s chief scientific officer, Martin Holst Lange, acknowledged the outcome without equivocation, noting that the drug had not achieved the cardiovascular benefit the company had hoped for even as he affirmed that the finding “does not change our strategic commitment to cardiovascular disease.”

The Weight of Precedent

To understand why this result carries weight beyond one drug and one company, it helps to revisit the trial that first legitimized the entire inflammatory hypothesis in cardiology. CANTOS, published in 2017 and led by Dr. Paul Ridker of Brigham and Women’s Hospital, tested canakinumab, an antibody targeting interleukin-1 beta, in more than ten thousand patients with a prior heart attack and elevated hsCRP. Its 150-milligram dose produced a statistically significant 15 percent reduction in major cardiovascular events, a result Ridker himself described as proof that lowering inflammation independent of cholesterol could reduce cardiovascular risk. That single trial reoriented an entire field of drug development toward the inflammatory cascade.

Ziltivekimab represented the next logical step in that lineage, moving one rung down the same biological pathway to interleukin-6, the downstream signal that IL-1 beta triggers and that ultimately produces the CRP levels doctors use to measure inflammatory risk in the clinic. The reasoning was elegant: target the signal closer to where CRP is actually generated, and the clinical benefit should follow with fewer of the off-target effects associated with blocking IL-1 beta further upstream. Ridker’s own earlier work on ziltivekimab helped build the case for this approach, giving him a rare vantage point across both chapters of the inflammation story.

ZEUS complicates that narrative considerably. It suggests that the relationship between a biomarker, its production pathway, and the disease process itself is not a straight line. Reducing IL-6 and CRP in the bloodstream, it turns out, is not the same as interrupting whatever combination of vascular, immune, and metabolic processes actually produces a heart attack. That distinction will now shape how the next generation of anti-inflammatory cardiovascular candidates gets designed and, more pointedly, how skeptically their biomarker data gets read before a company commits to an outcomes trial of this size.

The Market’s Verdict

Investors did not wait for nuance. Novo Nordisk’s Copenhagen-listed shares fell as much as 10 percent intraday before settling to a decline of roughly 8.6 percent, while the company’s American depositary receipts dropped 9.8 percent in premarket trading in New York. The reaction stripped several billion Danish kroner from a market capitalization that had stood near DKK 1.31 trillion for the Class B shares alone, a rapid repricing that reflected disappointment more than surprise.

That distinction matters. Deutsche Bank had flagged in mid-June, more than a month before the readout, that it expected ZEUS to miss, albeit with limited conviction, while maintaining a hold rating and a price target offering only modest upside from the stock’s prevailing level. The bank’s broader argument was structural rather than trial-specific: even a successful outcome would have offered limited valuation support given the roughly 30 billion dollar patent cliff Novo Nordisk faces in 2031 as its core franchise loses exclusivity. Friday’s decline, in other words, played out largely along lines the market had already sketched.

The sharper question is what the sell-off says about how investors now weight Novo Nordisk’s pipeline optionality. A company whose valuation rests overwhelmingly on its GLP-1 franchise gets relatively little credit in its share price for adjacent bets, which means those bets carry limited upside when they succeed and outsized punishment when they fail. That asymmetry is becoming a defining feature of how the market treats diversification efforts across large-cap pharmaceuticals more broadly, not just at Novo Nordisk.

A Pipeline Bet Inside a Larger Reckoning

Ziltivekimab’s origins trace back to Novo Nordisk’s 2020 acquisition of Corvidia Therapeutics, a deal structured around an upfront payment of 725 million dollars with total consideration reaching as much as 2.1 billion dollars upon regulatory and sales milestones. The bet was that Corvidia’s phase 2 data, which had shown meaningful reductions in inflammatory biomarkers among patients with chronic kidney disease, would carry through to a definitive outcomes trial and open a genuinely new category of cardiovascular medicine. Five years and one landmark trial later, that thesis has not held.

The timing compounds the difficulty. Novo Nordisk enters the second half of 2026 already guiding to a decline in adjusted sales and operating profit of between 4 and 12 percent at constant exchange rates, a range shaped by lower realized prices in the United States under the Most Favored Nations framework, the loss of semaglutide exclusivity in select international markets, and intensifying competitive pressure in obesity care. The board has nonetheless proposed raising its dividend and approved a fresh share repurchase program of up to 15 billion Danish kroner, a signal that management still trusts the durability of its core metabolic franchise even as the newer cardiovascular bet falters.

Novo Nordisk confirmed that the ZEUS outcome will not alter its 2026 profit guidance, though it will produce a non-cash impairment charge in the third quarter, an accounting consequence of writing down the value assigned to ziltivekimab’s cardiovascular indication rather than a change to underlying operations. It is a reminder that clinical failure and financial failure are not always the same event, even when the market treats them as one on the day the news breaks.

What the Next Eighteen Months Will Decide

Ziltivekimab’s story does not end with ZEUS. Two further outcomes trials, HERMES in heart failure with mildly reduced or preserved ejection fraction and ARTEMIS in patients following an acute heart attack, are continuing and are expected to report in the first half of 2027. Both populations differ meaningfully from the ZEUS cohort in how inflammation interacts with cardiac and vascular physiology, which means neither trial’s outcome is fully predictable from Friday’s result, however tempting that inference may be.

A positive signal in either study would keep the inflammatory hypothesis alive within Novo Nordisk’s pipeline and validate the underlying science even after this setback. A second disappointment would raise a harder question, not about the biology of IL-6 in isolation, but about whether Novo Nordisk’s cardiovascular ambitions were ever going to be judged on their own merits or simply absorbed as a rounding error against the scale of its obesity franchise.

For senior allocators, the lesson of ZEUS is less about one antibody and more about how binary science gets priced inside a company whose core business has already achieved its own kind of scale and maturity. Novo Nordisk’s next act will be written mostly by Wegovy’s successors. HERMES and ARTEMIS will simply determine whether cardiovascular disease remains a credible second chapter or fades into a costly, well-intentioned footnote.